137 related articles for article (PubMed ID: 10759364)
1. Intranasal midazolam in piglets: pharmacodynamics (0.2 vs 0.4 mg/kg) and pharmacokinetics (0.4 mg/kg) with bioavailability determination.
Lacoste L; Bouquet S; Ingrand P; Caritez JC; Carretier M; Debaene B
Lab Anim; 2000 Jan; 34(1):29-35. PubMed ID: 10759364
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults.
Berg AK; Myrvik MJ; Van Ess PJ
Epilepsy Behav; 2017 Jun; 71(Pt A):51-59. PubMed ID: 28544992
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers.
Knoester PD; Jonker DM; Van Der Hoeven RT; Vermeij TA; Edelbroek PM; Brekelmans GJ; de Haan GJ
Br J Clin Pharmacol; 2002 May; 53(5):501-7. PubMed ID: 11994056
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.
Bancke LL; Dworak HA; Rodvold KA; Halvorsen MB; Gidal BE
Epilepsia; 2015 Nov; 56(11):1723-31. PubMed ID: 26332539
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation.
Schrier L; Zuiker R; Merkus FW; Klaassen ES; Guan Z; Tuk B; van Gerven JM; van der Geest R; Groeneveld GJ
Br J Clin Pharmacol; 2017 Apr; 83(4):721-731. PubMed ID: 27780297
[TBL] [Abstract][Full Text] [Related]
6. Intranasal midazolam: a comparison of two delivery devices in human volunteers.
Dale O; Nilsen T; Loftsson T; Hjorth Tønnesen H; Klepstad P; Kaasa S; Holand T; Djupesland PG
J Pharm Pharmacol; 2006 Oct; 58(10):1311-8. PubMed ID: 17034653
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas.
Aarnes TK; Fry PR; Hubbell JA; Bednarski RM; Lerche P; Chen W; Bei D; Liu Z; Lakritz J
Am J Vet Res; 2013 Feb; 74(2):294-9. PubMed ID: 23363357
[TBL] [Abstract][Full Text] [Related]
8. Bioavailability of a novel midazolam gel after intranasal administration in dogs.
Eagleson JS; Platt SR; Strong DL; Kent M; Freeman AC; Nghiem PP; Zheng B; White CA
Am J Vet Res; 2012 Apr; 73(4):539-45. PubMed ID: 22452501
[TBL] [Abstract][Full Text] [Related]
9. Intranasal administration of midazolam: pharmacokinetic and pharmacodynamic properties and sedative potential.
Fukuta O; Braham RL; Yanase H; Kurosu K
ASDC J Dent Child; 1997; 64(2):89-98. PubMed ID: 9188997
[TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic study of midazolam in dogs: nasal drop vs. atomizer administration.
Henry RJ; Ruano N; Casto D; Wolf RH
Pediatr Dent; 1998; 20(5):321-6. PubMed ID: 9803431
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam.
Haschke M; Suter K; Hofmann S; Witschi R; Fröhlich J; Imanidis G; Drewe J; Briellmann TA; Dussy FE; Krähenbühl S; Surber C
Br J Clin Pharmacol; 2010 Jun; 69(6):607-16. PubMed ID: 20565452
[TBL] [Abstract][Full Text] [Related]
12. Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers.
Pecking M; Montestruc F; Marquet P; Wodey E; Homery MC; Dostert P
Br J Clin Pharmacol; 2002 Oct; 54(4):357-62. PubMed ID: 12392582
[TBL] [Abstract][Full Text] [Related]
13. Development of a pharmacokinetic and pharmacodynamic model for intranasal administration of midazolam in older adults: a single-site two-period crossover study.
Barends C; den Daas I; Driesens M; Visser A; Absalom A; Colin P
Br J Anaesth; 2023 Aug; 131(2):284-293. PubMed ID: 37268446
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of midazolam after intranasal administration.
Burstein AH; Modica R; Hatton M; Forrest A; Gengo FM
J Clin Pharmacol; 1997 Aug; 37(8):711-8. PubMed ID: 9378843
[TBL] [Abstract][Full Text] [Related]
15. Evaluating Clinical Effectiveness and Pharmacokinetic Profile of Atomized Intranasal Midazolam in Children Undergoing Laceration Repair.
Mellion SA; Bourne D; Brou L; Brent A; Adelgais K; Galinkin J; Wathen J
J Emerg Med; 2017 Sep; 53(3):397-404. PubMed ID: 28992870
[TBL] [Abstract][Full Text] [Related]
16. Intranasal administration of midazolam in a cyclodextrin based formulation: bioavailability and clinical evaluation in humans.
Gudmundsdottir H; Sigurjonsdottir JF; Masson M; Fjalldal O; Stefansson E; Loftsson T
Pharmazie; 2001 Dec; 56(12):963-6. PubMed ID: 11802661
[TBL] [Abstract][Full Text] [Related]
17. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation.
Wermeling DP; Record KA; Archer SM; Rudy AC
Epilepsy Res; 2009 Feb; 83(2-3):124-32. PubMed ID: 19046855
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of midazolam following intravenous and intramuscular administration to sheep.
Simon BT; Scallan EM; O O; Ebner LS; Cerullo MN; Follette C; Cox SK; Doherty TJ; Lizarraga I
Am J Vet Res; 2017 May; 78(5):539-549. PubMed ID: 28441044
[TBL] [Abstract][Full Text] [Related]
19. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
[TBL] [Abstract][Full Text] [Related]
20. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers.
Hardmeier M; Zimmermann R; Rüegg S; Pflüger M; Deuster S; Suter K; Donzelli M; Drewe J; Krähenbühl S; Fuhr P; Haschke M
Clin Pharmacol Ther; 2012 May; 91(5):856-62. PubMed ID: 22453191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
